Overexpression of Bcl-2, SOCS 1, 3 and Cdh 1, 2 are associated with the early neoplasic changes in modified 4-nitroquinoline 1-oxide-induced murine oral cancer model.

BACKGROUND: The objective was to assess histopathological changes and the expression of proliferating cell nuclear antigen (PCNA), Bcl-2, suppressor of cytokine signaling (SOCS) 1 and 3, Vimentin, TWIST1, and Cdh 1 and 2 in early stages of experimental oral carcinogenesis process using a shorter period of exposure to 4-nitroquinoline oxide (4-NQO) model. METHODS: In this study, 20 rats were divided into control group (n = 10), sacrificed on the first day of the experiment, and experimental group (n = 10) treated with 50 ppm of 4-NQO solution dissolved in drinking water for 8 and 12 weeks. The histological sections were stained with H&E or subjected to immunohistochemistry for detecting PCNA, Bcl-2, SOCS 1 and 3, and STAT 3. Some specimens were used for verification of Vimentin expression, Cdh 1, Cdh 2, and TWIST1 by RT-qPCR. RESULTS: At both 8 and 12 weeks, morphological changes occurred mainly in the posterior portion of the tongue and were limited to the epithelial tissue, including moderate to severe dysplasia at 8 weeks, and severe dysplasia with exacerbation of atypical cells at 12 weeks. Expression of SOCS 1 and 3 increased from 8 to 12 weeks (P < 0.05), whereas STAT 3 expression was reduced mainly at 12 weeks (P < 0.05) in comparison with the control group. The expression of all epithelial-mesenchymal transition markers (EMT) was increased after 12 weeks, reaching statistical significance (P < 0.05) for Cdh 1 and 2. CONCLUSIONS: Together, the results suggested that overexpression of Bcl-2, SOCS 1 and 3, and Cdh 1 and 2 is associated with the early neoplasic changes in modified 4-nitroquinoline 1-oxide-induced murine oral cancer model.

Relevance of the myeloid differentiation factor 88 (MyD88) on RANKL, OPG, and nod expressions induced by TLR and IL-1R signaling in bone marrow stromal cells.

The myeloid differentiation factor 88 (MyD88) plays a pivotal role in Toll-like receptor (TLR)- and interleukin-1 receptor (IL-1R)-induced osteoclastogenesis. We examined the role of MyD88 on p38 mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) activation and nucleotide-binding oligomerization domain (Nod) induction by lipopolysaccharide (LPS) and IL-1 beta, and their effect on receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) production in bone marrow stromal cell (BMSC). RANKL, Nod1, Nod2, NF-κB, and p38 protein levels were determined by Western blot. Nod2 was stimulated with muramyl dipeptide (MDP) prior to TLR4 stimulation with LPS. MyD88 deficiency markedly inhibited RANKL expression after LPS stimulation and increased OPG messenger RNA (mRNA) production. Also, MyD88 was necessary for NF-κB and p38 MAPK activation. MDP alone did not induce RANKL and OPG expressions; however, when combined with LPS, their expressions were significantly increased (p < 0.05). Our results support that MyD88 signaling has a pivotal role in osteoclastogenesis thought NF-κB and p38 activation. Nod2 and especially Nod1 levels were influenced by MyD88.

Curcumin abrogates LPS-induced pro-inflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1, -3 and p38 MAPK.

Curcumin is the active compound in the extract of Curcuma longa rhizomes with anti-inflammatory properties mediated by inhibition of intracellular signalling. SOCS and MAPKinases are involved in the signalling events controlling the expression of IL-6, TNF-α and PGE2, which have important roles on chronic inflammatory diseases. The aim was to assess if these pathways are involved in curcumin-mediated effects on LPS-induced expression of these cytokines in macrophages. RAW 264.7 murine macrophages were stimulated with Escherichia coli LPS in the presence and absence of non-cytotoxic concentrations of curcumin. Curcumin potently inhibited LPS-induced expression of IL-6, TNF-α and COX-2 mRNA and prevented LPS-induced inhibition of SOCS-1 and -3 expression and the inhibition of the activation of p38 MAPKinase by modulation of its nuclear translocation. In conclusion, curcumin potently inhibits expression of LPS-induced inflammatory cytokines in macrophages via mechanisms that involve modulation of expression and activity of SOCS-1 and SOCS-3 and of p38 MAPK.

Differential regulation of MMP-13 expression in two models of experimentally induced periodontal disease in rats.

OBJECTIVE: Evaluate expression of MMP-13 during the course of two models experimentally induced periodontal disease in rats. DESIGN: Expression of MMP-13 at mRNA and protein levels was studied, respectively, by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting. Two experimental models were used: LPS injections and ligature placement. 30mug of LPS from Eschericia coli was injected twice a week into the palatal aspect of upper molars. Ligatures were placed at the gingival margin around lower first molars. Controls received injections of PBS vehicle and no ligatures on lower molars. Samples were collected 5, 15 and 30 days after initiation of periodontal disease and processed for extraction of total RNA, total protein, and routinely processed for histology. RESULTS: Both experimental models produced a significant increase on the inflammatory infiltrate that paralleled elevated levels of MMP-13 mRNA and protein at 5 and 15 days. The LPS model was associated with a sustained level of inflammation and increased MMP-13 mRNA throughout the 30 days, whereas the ligature model showed a decrease on the severity of inflammation and MMP-13 mRNA at the 30-day period. Interestingly, MMP-13 protein levels were diametrically contrary to the mRNA levels. CONCLUSION: MMP-13 expression during LPS- and ligature-induced experimental periodontal disease follows the increase on severity of inflammation at the earliest periods. At 30 days, there is a decrease on the severity of inflammation on the ligature model associated with decreased MMP-13 mRNA. There is a lack of transcription-translation coupling of MMP-13 gene in both experimental models.

Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats.

One of the more serious complications following transplantation is the development of post-transplantation diabetes mellitus (PTDM), which has a major impact on the quality of life, with effects ranging from the control of glycemia times to increased susceptibility to infections and cardiovascular complications. It has been suggested that immunosuppressive therapy, mainly tacrolimus therapy, may be an important factor in the development of PTDM. There is a lack of studies that explore the effects of long-term tacrolimus on PTDM in animal protocols. The objective of this study was therefore to evaluate the effects of long-term therapy with tacrolimus in rats. One group was treated with tacrolimus, injected subcutaneously, in a daily dose of 1 mg/kg of body weight. The chosen dose was sufficient to achieve therapeutic tacrolimus serum levels. The experimental periods were 60, 120, 180 and 240 days. One group was used as control and received daily subcutaneous injections of saline solution during all periods. A tendency towards increased glycemia levels during the initial periods (60 and 120 days) was observed. However, at 180 and 240 days, the glycemia levels were not statistically different from that of the control group of the same period. It may thus be concluded that the deleterious effects of tacrolimus therapy on glycemia may be a time-related side effect.

Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats

One of the more serious complications following transplantation is the development of post-transplantation diabetes mellitus (PTDM), which has a major impact on the quality of life, with effects ranging from the control of glycemia times to increased susceptibility to infections and cardiovascular complications. It has been suggested that immunosuppressive therapy, mainly tacrolimus therapy, may be an important factor in the development of PTDM. There is a lack of studies that explore the effects of long-term tacrolimus on PTDM in animal protocols. The objective of this study was therefore to evaluate the effects of long-term therapy with tacrolimus in rats. One group was treated with tacrolimus, injected subcutaneously, in a daily dose of 1 mg/kg of body weight. The chosen dose was sufficient to achieve therapeutic tacrolimus serum levels. The experimental periods were 60, 120, 180 and 240 days. One group was used as control and received daily subcutaneous injections of saline solution during all periods. A tendency towards increased glycemia levels during the initial periods (60 and 120 days) was observed. However, at 180 and 240 days, the glycemia levels were not statistically different from that of the control group of the same period. It may thus be concluded that the deleterious effects of tacrolimus therapy on glycemia may be a time-related side effect.

Uma das mais sérias complicações pós-transplante é o desenvolvimento de Diabetes Mellitus Pós-Transplante (DMPT), que irá produzir um grande impacto na qualidade de vida, com variações do controle glicêmico, aumentando a susceptibilidade a infecções e complicações cardiovasculares. Tem sido sugerido que a terapia imunossupressora, principalmente com tacrolimo, pode ser um importante fator no desenvolvimento de DMPT. Existem atualmente poucos estudos explorando os efeitos de um longo período de terapia com tacrolimo sobre DMPT em protocolos animais. Portanto, o objetivo deste estudo foi avaliar o efeito glicêmico de uma terapia por longo período com tacrolimo em ratos. Um grupo foi tratado com tacrolimo com doses diárias subcutâneas de 1 mg/kg de peso corporal. A escolha dessa dose foi suficiente para a obtenção dos níveis séricos terapêuticos desejados com tacrolimo. Os períodos experimentais foram 60, 120, 180 e 240 dias. Outro grupo foi usado como controle e recebeu injeções salinas subcutâneas diariamente durante todos os períodos. Houve uma tendência ao aumento do nível glicêmico nos períodos iniciais (60 e 120 dias). Entretanto, após 180 e 240 dias, os níveis de glicemia não foram estatisticamente diferentes dos obtidos nos grupos controles de mesmo período. Assim, pode-se concluir que os efeitos glicêmicos adversos provocados pela terapia com tacrolimo podem ser relacionados ao tempo.

Avaliação longitudinal de pacientes com disfunções têmporomandibulares tratados com placas oclusais, aconselhamento e farmacoterapia / Longitudinal evaluation of temporomandibular disorders patients managed with occlusal splints, counsellinfg and medications

Tendo em vista o amplo uso das placas oclusais em pacientes com DTM e a mínima utilização de aconselhamento/farmacoterapia como modalidades terapêuticas, este trabalho teve como objetivoavaliar os pacientes tratados na Clínica de Oclusão e Dores Orofaciais da Faculdade de Odontologia deAraraquara - UNESP, para verificar o percentual de pacientes tratados com placas oclusais e farmacoterapia/aconselhamento, bem como o índice de sucesso das modalidades terapêuticas empregadas. A amostra inicial foi de 258 pacientes (63 do gênero masculino e do 195 gênerofeminino), sendo que 62 (24%) tiveram indicação para o uso de placa oclusal e aconselhamento e para 196 (76%) foi recomendado apenas o aconselhamento e/ou farmacoterapia, sem uso de nenhum tipode placa oclusal. Quanto ao sucesso das terapias empregadas, houve melhora da sintomatologia dolorosa em 79,2% dos pacientes que usaram a placa oclusal comparado a 75% dos pacientes aos quais foi indicado apenas aconselhamento e/ou farmacoterapia. Após 2 a 3 anos da finalização dotratamento, 41,6% dos pacientes não utilizavam mais as placas oclusais e 58,4% só a utilizavam durante a noite. A conclusão foi que a maior parte dos pacientes da Clínica de Dores Orofaciais foi tratada com aconselhamento e/ou farmacoterapia (76%) sem a utilização de placas oclusais. Ambas as modalidades se mostraram eficazes na redução dos sinais e sintomas de DTM. Sendo assim, pelo índice de sucesso obtido e ainda pelos pacientes não utilizarem mais as placas com o decorrer do tempo, o uso do aconselhamento associado à farmacoterapia deveria ser uma modalidade terapêutica mais explorada pelos profissionais

Taking into consideration that occlusal splints have been largely used for the management of TMD signsand symptoms and that self-care/medications are rarely utilized, the aim of this study was to evaluate patients treated at the Occlusion,TMDand Orofacial Pain Clinic, Araraquara School of Dentistry, in orderto obtain the number of patients treated with occlusal splints, self-care and medications, as well as the index of effectiveness of the modalities that had been indicated. Study sample was comprised of 258 patients (63 male and 195 female). 62 (24%) had indication for the use of an occlusal splint and self-care, and for the others 196 patients (76%) only self-care and medications were utilized, with no use of anykind of occlusal splint. Regarding the effectiveness of the treat modalities, occlusal splint was effective in the reduction of TMD pain in 79, 2% of the patients as opposed to 75% of the patients who were treated with self-care and medications only. After 2 to 3 years of occlusal splint therapy, 41,6% of the patients were not using the splint anymore and the other 58,4% were using it just at bedtime, not in an everyday basis. Authors concluded that for the most part of the patients treated at our Clinic, self-care and medications were effective (76%) without the use of an occlusal splint. All the groups had the same success rate. Therefore, since both therapies were effective and considering the fact that patients do not use an occlusal splint for the rest of their lives, the use of self-care associated with medications should be more utilized in the clinical management of TMD symptoms